Your session is about to expire
← Back to Search
Non-invasive Brain Stimulation
TMS for Cerebellar Ataxia
N/A
Waitlist Available
Led By Amanda S Therrien, PhD
Research Sponsored by Albert Einstein Healthcare Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Meet safety criteria for receipt of transcranial magnetic stimulation
Normal or corrected-to-normal vision
Must not have
Extrapyramidal signs on neurologic examination
Cognitive or attention deficits that interfere with testing, the capacity to understand and follow task instructions, or the capacity to provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if brain activity can predict and improve motor learning in people with cerebellar ataxia. It uses non-invasive brain stimulation to adjust brain activity and tests if this helps patients learn new movement skills better.
Who is the study for?
This trial is for individuals with cerebellar ataxia due to cerebellar degeneration. Participants must have normal or corrected vision and hearing, and meet safety criteria for transcranial magnetic stimulation (TMS). They cannot join if they have drug abuse history, sensory loss in arms, cognitive issues affecting testing or consent, or arm injuries causing pain.
What is being tested?
The study aims to see if the activity level in the primary motor cortex can predict how well people with cerebellar damage learn motor skills. It also tests whether using TMS to change motor cortex activity improves their ability to learn new movements.
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in very rare cases. Most side effects are mild and temporary.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am cleared to receive brain stimulation treatment.
Select...
My vision is normal or corrected to normal with glasses or contacts.
Select...
My hearing is normal or corrected to normal.
Select...
I have been diagnosed with cerebellar ataxia due to cerebellar degeneration.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have unusual movements or symptoms like Parkinson's.
Select...
I can understand and follow instructions without any cognitive issues.
Select...
I experience numbness or loss of sensation in my arms.
Select...
I have an injury or pain in my arms.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cortical Silent Period
International Cooperative Ataxia Rating Scale Limb Coordination Sub-Score
International Cooperative Ataxia Rating Scale Total Score
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: rTMS InterventionExperimental Treatment1 Intervention
In aim 2 of the study, participants receive a repetitive transcranial magnetic stimulation intervention called theta burst stimulation (TBS) to study its effect on motor learning behavior. All participants will complete 3 sessions in which they will receive continuous TBS, intermittent TBS, or sham TBS before completing a behavioral motor learning task. The order of TBS sessions will be counter-balanced across participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation (TMS)
2018
Completed Phase 4
~550
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Non-invasive brain stimulation, such as transcranial magnetic stimulation (TMS), targets the primary motor cortex to modulate its activity. This technique uses magnetic fields to stimulate nerve cells in the brain, which can enhance motor learning and improve motor function.
For patients with Cerebellar Ataxia, this is particularly important as the cerebellum plays a crucial role in coordinating movement and balance. By modulating the activity of the primary motor cortex, non-invasive brain stimulation can potentially compensate for the impaired cerebellar function, leading to better motor control and reduced ataxic symptoms.
Find a Location
Who is running the clinical trial?
Albert Einstein Healthcare NetworkLead Sponsor
64 Previous Clinical Trials
868,697 Total Patients Enrolled
Medical University of South CarolinaOTHER
977 Previous Clinical Trials
7,400,975 Total Patients Enrolled
Amanda S Therrien, PhDPrincipal InvestigatorMoss Rehabilitation Research Institute
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am cleared to receive brain stimulation treatment.I have unusual movements or symptoms like Parkinson's.I can understand and follow instructions without any cognitive issues.You have a history of drinking too much alcohol or using illegal drugs.I experience numbness or loss of sensation in my arms.My vision is normal or corrected to normal with glasses or contacts.My hearing is normal or corrected to normal.I have been diagnosed with cerebellar ataxia due to cerebellar degeneration.I have an injury or pain in my arms.
Research Study Groups:
This trial has the following groups:- Group 1: rTMS Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.